Analyst Price Targets — RIGL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 5, 2025 8:47 pm | — | Jefferies | $42.00 | $37.85 | TheFly | Rigel Pharmaceuticals upgraded to Buy from Hold at Jefferies |
| November 5, 2025 1:32 pm | — | Cantor Fitzgerald | $38.00 | $37.63 | TheFly | Rigel Pharmaceuticals price target raised to $38 from $32 at Cantor Fitzgerald |
| August 17, 2022 7:22 am | — | Piper Sandler | $2.00 | $1.56 | Benzinga | Piper Sandler Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $2 |
| June 8, 2022 3:09 pm | Eun Yang | Jefferies | $1.00 | $0.71 | TheFly | Rigel Pharmaceuticals downgraded to Hold from Buy at Jefferies |
Latest News for RIGL
Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Both Iovance Biotherapeutics IOVA and Rigel Pharmaceuticals RIGL are small-cap companies focused on the successful commercialization of their marketed products.
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 3, 2026.
Rigel Pharmaceuticals RIGL had an encouraging year in 2025. The company is yet to report its fourth-quarter and full-year 2025 results, but preliminary figures released last month point to another strong finish — driven primarily by the lead marketed drug Tavalisse.
Rigel Pharmaceuticals climbs 59% in a year as Tavalisse anchors growth, oncology gains traction and 2026 guidance points to sustained momentum.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RIGL.
U.S. House Trading
No House trades found for RIGL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.